PortfoliosLab logoPortfoliosLab logo
MRK vs. AMGN
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

MRK vs. AMGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Merck & Co., Inc. (MRK) and Amgen Inc. (AMGN). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

MRK vs. AMGN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
MRK
Merck & Co., Inc.
15.13%9.79%-6.26%1.01%49.42%1.75%-7.20%22.27%39.95%-1.49%
AMGN
Amgen Inc.
8.24%29.67%-6.77%13.46%20.43%0.87%-1.99%27.60%15.23%22.27%

Fundamentals

Market Cap

MRK:

$299.28B

AMGN:

$191.05B

EPS

MRK:

$7.30

AMGN:

$14.23

PE Ratio

MRK:

16.47

AMGN:

24.73

PEG Ratio

MRK:

0.01

AMGN:

1.42

PS Ratio

MRK:

4.63

AMGN:

5.19

PB Ratio

MRK:

5.77

AMGN:

22.07

Total Revenue (TTM)

MRK:

$65.01B

AMGN:

$36.74B

Gross Profit (TTM)

MRK:

$52.98B

AMGN:

$24.70B

EBITDA (TTM)

MRK:

$28.80B

AMGN:

$16.33B

Returns By Period

In the year-to-date period, MRK achieves a 15.13% return, which is significantly higher than AMGN's 8.24% return. Both investments have delivered pretty close results over the past 10 years, with MRK having a 12.31% annualized return and AMGN not far behind at 11.88%.


MRK

1D
1.85%
1M
-2.13%
YTD
15.13%
6M
45.62%
1Y
38.88%
3Y*
7.42%
5Y*
13.86%
10Y*
12.31%

AMGN

1D
0.82%
1M
-9.35%
YTD
8.24%
6M
26.44%
1Y
16.48%
3Y*
16.93%
5Y*
10.56%
10Y*
11.88%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MRK vs. AMGN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MRK
MRK Risk / Return Rank: 7979
Overall Rank
MRK Sharpe Ratio Rank: 8282
Sharpe Ratio Rank
MRK Sortino Ratio Rank: 7878
Sortino Ratio Rank
MRK Omega Ratio Rank: 7676
Omega Ratio Rank
MRK Calmar Ratio Rank: 8080
Calmar Ratio Rank
MRK Martin Ratio Rank: 7979
Martin Ratio Rank

AMGN
AMGN Risk / Return Rank: 6262
Overall Rank
AMGN Sharpe Ratio Rank: 6363
Sharpe Ratio Rank
AMGN Sortino Ratio Rank: 5757
Sortino Ratio Rank
AMGN Omega Ratio Rank: 5555
Omega Ratio Rank
AMGN Calmar Ratio Rank: 6767
Calmar Ratio Rank
AMGN Martin Ratio Rank: 6767
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MRK vs. AMGN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Merck & Co., Inc. (MRK) and Amgen Inc. (AMGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


MRKAMGNDifference

Sharpe ratio

Return per unit of total volatility

1.34

0.57

+0.77

Sortino ratio

Return per unit of downside risk

1.96

1.03

+0.93

Omega ratio

Gain probability vs. loss probability

1.25

1.13

+0.12

Calmar ratio

Return relative to maximum drawdown

2.19

1.15

+1.04

Martin ratio

Return relative to average drawdown

5.34

2.80

+2.54

MRK vs. AMGN - Sharpe Ratio Comparison

The current MRK Sharpe Ratio is 1.34, which is higher than the AMGN Sharpe Ratio of 0.57. The chart below compares the historical Sharpe Ratios of MRK and AMGN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


MRKAMGNDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.34

0.57

+0.77

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.60

0.44

+0.15

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.54

0.48

+0.06

Sharpe Ratio (All Time)

Calculated using the full available price history

0.49

0.61

-0.13

Correlation

The correlation between MRK and AMGN is 0.35, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

MRK vs. AMGN - Dividend Comparison

MRK's dividend yield for the trailing twelve months is around 2.76%, which matches AMGN's 2.75% yield.


TTM20252024202320222021202020192018201720162015
MRK
Merck & Co., Inc.
2.76%3.12%3.14%2.72%2.52%3.41%3.03%2.48%2.60%3.36%3.14%3.43%
AMGN
Amgen Inc.
2.75%2.91%3.45%2.96%2.95%3.13%2.78%2.41%2.71%2.65%2.74%1.95%

Drawdowns

MRK vs. AMGN - Drawdown Comparison

The maximum MRK drawdown since its inception was -68.61%, which is greater than AMGN's maximum drawdown of -63.48%. Use the drawdown chart below to compare losses from any high point for MRK and AMGN.


Loading graphics...

Drawdown Indicators


MRKAMGNDifference

Max Drawdown

Largest peak-to-trough decline

-68.61%

-63.48%

-5.13%

Max Drawdown (1Y)

Largest decline over 1 year

-15.67%

-15.35%

-0.32%

Max Drawdown (5Y)

Largest decline over 5 years

-43.44%

-24.86%

-18.58%

Max Drawdown (10Y)

Largest decline over 10 years

-43.44%

-24.86%

-18.58%

Current Drawdown

Current decline from peak

-4.04%

-9.35%

+5.31%

Average Drawdown

Average peak-to-trough decline

-18.89%

-16.80%

-2.09%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.44%

6.51%

+0.93%

Volatility

MRK vs. AMGN - Volatility Comparison

The current volatility for Merck & Co., Inc. (MRK) is 5.85%, while Amgen Inc. (AMGN) has a volatility of 6.34%. This indicates that MRK experiences smaller price fluctuations and is considered to be less risky than AMGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


MRKAMGNDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.85%

6.34%

-0.49%

Volatility (6M)

Calculated over the trailing 6-month period

19.79%

20.60%

-0.81%

Volatility (1Y)

Calculated over the trailing 1-year period

29.08%

29.02%

+0.06%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

23.30%

23.87%

-0.57%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

22.68%

24.74%

-2.06%

Financials

MRK vs. AMGN - Financials Comparison

This section allows you to compare key financial metrics between Merck & Co., Inc. and Amgen Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


6.00B8.00B10.00B12.00B14.00B16.00B18.00BAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
16.40B
9.87B
(MRK) Total Revenue
(AMGN) Total Revenue
Values in USD except per share items

MRK vs. AMGN - Profitability Comparison

The chart below illustrates the profitability comparison between Merck & Co., Inc. and Amgen Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%70.0%80.0%90.0%AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
92.7%
69.8%
Portfolio components
MRK - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported a gross profit of 15.20B and revenue of 16.40B. Therefore, the gross margin over that period was 92.7%.

AMGN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Amgen Inc. reported a gross profit of 6.89B and revenue of 9.87B. Therefore, the gross margin over that period was 69.8%.

MRK - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported an operating income of 8.74B and revenue of 16.40B, resulting in an operating margin of 53.3%.

AMGN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Amgen Inc. reported an operating income of 2.72B and revenue of 9.87B, resulting in an operating margin of 27.6%.

MRK - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Merck & Co., Inc. reported a net income of 2.96B and revenue of 16.40B, resulting in a net margin of 18.1%.

AMGN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Amgen Inc. reported a net income of 1.33B and revenue of 9.87B, resulting in a net margin of 13.5%.